TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3048935
Drug: Ampicillin, 1
Normalized name: Ampicillin, 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 1 gm, four times daily, and metronidazole, 0.5 gm, three times daily, for 72 hours.
Study: 23211454
Drug: Lavender and
Normalized name: PureLogic Hand Sanitizer French Lavender and Lemon Mint 6 Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender and Tea tree oils (group T) applied twice a day for 3 months
Study: 23211454
Drug: Placebo (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (group P) applied twice a day for 3 months
Study: 17301736
Drug: Amiodarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (400 mg/day for 3 days)
Study: 15390234
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of ascorbate
Study: 22076584
Drug: Nurse-prepared intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nurse-prepared intra-arterial flush solutions with longer hang times
Study: 22076584
Drug: Nurse-prepared intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nurse-prepared intra-arterial flush solutions
Study: 9499493
Drug: Intracoronary dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary dipyridamole (0.5 mg/kg body weight)
Study: 9849048
Drug: Conventional pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pretreatment (heparin 15000 IE, aspirin 500 mg i.v.)
Study: 2526009
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 400 mg teicoplanin 1, 3, 6 or 12 h prior to surgery
Study: 1097143
Drug: Amiloride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (20 mg/day)
Study: 1097143
Drug: Frusemide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (80 mg/day)
Study: 1097143
Drug: Chlorothiazide (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide (1000 mg/day)
Study: 28407660
Drug: Calcium, 200
Normalized name: Fenoprofen Calcium, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium, 200 IU Vitamin D, and 90 µg Vitamin K supplementation
Study: 8041983
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of lidocaine 2% (group B)
Study: 2648150
Drug: Surfactant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (100 mg of phospholipid per kilogram of body weight [4 ml per kilogram])
Study: 2648150
Drug: Air placebo
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air placebo (4 ml per kilogram)
Study: 4825114
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin prophylaxis (5,000 IU mucous heparin sodium given two hours preoperatively and for five days post operatively)
Study: 21803113
Drug: Rivastigmine 6
Normalized name: rivastigmine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 6 mg
Study: 31430484
Drug: Cocaine administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine administration on day 10
Study: 28410818
Drug: Protocol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol group received initial and additional doses of rocuronium (0.6 mg.kg−1 and 10 mg, respectively); blockade reversal with neostigmine (50 μg.kg−1); time ≥ 15 minutes between reversion and extubation.
Study: 28410818
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received initial and additional doses of rocuronium, blockade reversal, neostigmine dose, and extubation time at the discretion of the anesthesiologist.
Study: 24803523
Drug: Clinical dose
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical dose of esmolol
Study: 24803523
Drug: Esmolol-treated groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol-treated groups (both clinical and subclinical doses)
Study: 23474997
Drug: Taekwondo training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taekwondo training for 1 hour daily over three months
Study: 16685298
Drug: Chlorhexidine rinse
Normalized name: chlorhexidine Mouthwash [Denti-Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine rinse twice daily with 15 ml for 30 seconds for one week before and one week after surgery (group I)
Study: 16685298
Drug: Chlorhexidine rinse
Normalized name: chlorhexidine Mouthwash [Denti-Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine rinse twice daily with 15 ml for 30 seconds for one week after surgery (group II)
Study: 9431832
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone 1000 microg day-1 (F1000)
Study: 9431832
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone 2000 microg day-1 (F2000)
Study: 9431832
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 50 mg (PRED)
Study: 9230722
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo (PL)
Study: 8099863
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg isamoltane
Study: 8099863
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isamoltane
Study: 3545744
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Nisoldipine
Study: 3545744
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Nisoldipine
Study: 3545744
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Nisoldipine
Study: 24444117
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate administered in the prehospital setting
Study: 19708473
Drug: Sensory Integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integrative (SI) therapy
Study: 12229307
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg daily for three days
Study: 12592331
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP)
Study: 7915989
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone (LDMP)
Study: 2643500
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium 10 units/mL
Study: 31277885
Drug: Warfarin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (group 2)
Study: 17445933
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart with metformin 500 mg t.i.d. for 90 days
Study: 17445933
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin with metformin 500 mg t.i.d. for 90 days
Study: 15600248
Drug: Maribavir (DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maribavir (DNA synthesis inhibitor)
Study: 15899652
Drug: alpha-tocopherol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (800 mg/day)
Study: 8621850
Drug: Zileuton (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (600 mg orally four times a day for 8 days)
Study: 1742650
Drug: Threshold allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold allergen dose
Study: 1742650
Drug: Higher allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher allergen dose (x 10 threshold)
Study: 7139396
Drug: d‐tubocurarine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine 0.04 mg.kg‐1 and atropine 0.01 mg.kg‐1
Study: 7139396
Drug: d‐tubocurarine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine 0.04 mg.kg‐1 only
Study: 29524000
Drug: OLE in
Normalized name: fomepizole Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLE in solution (25 g sucrose)
Study: 29524000
Drug: OLE in
Normalized name: fomepizole Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLE in capsules or solution (50 g sucrose or glucose)
Study: 24531433
Drug: Contrast water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast water therapy (alternating 1 minute 38° C and 1 minute 15° C water immersion)
Study: 24531433
Drug: Contrast water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast water therapy and contrast showers
Study: 20403600
Drug: Sedative music
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative music for 30 minutes
Study: 12047490
Drug: nabumetone 1000
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabumetone 1000 mg twice daily
Study: 12047490
Drug: meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 7.5 mg twice daily
Study: 12047490
Drug: indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 50 mg
Study: 7673658
Drug: Cyproheptadine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine augmentation of haloperidol
Study: 30691750
Drug: No thermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thermal agent (control)
Study: 29441909
Drug: Esmolol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.3 mg/kg before intubation, continuous perfusion at 50 μg/kg/min during operation)
Study: 24081158
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (rhGH) (33-50 μg kg(‐1) day(‐1))
Study: 23747582
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioral Therapy (CBT)
Study: 20084879
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of PCV7
Study: 16948824
Drug: Broad-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-band UVB phototherapy plus oral acyclovir (800 mg five times a day for 10 days); UVB starting at 20 mJ/cm², increasing by 10 mJ/cm² per session, max 100 mJ/cm², 3 times a week for up to 15 sessions.
Study: 16948824
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg five times a day for 10 days) only (control group).
Study: 11421836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of droperidol 15 microg kg(‐1) and ondansetron 100 microg kg(‐1)
Study: 3566859
Drug: Digoxin-Pharbita 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin-Pharbita 0.25 mg (Product A)
Study: 3566859
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug B (Product B)
Study: 31799993
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of Antidepressant Medication (ADM)
Study: 31799993
Drug: Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Medication (ADM) alone
Study: 25248345
Drug: Subunit Agrippal
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit Agrippal vaccine
Study: 21883001
Drug: Haematococcus astaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haematococcus astaxanthin (ASX) 5 mg
Study: 21883001
Drug: Haematococcus astaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haematococcus astaxanthin (ASX) 20 mg
Study: 21883001
Drug: Haematococcus astaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haematococcus astaxanthin (ASX) 40 mg
Study: 10630442
Drug: L. acidophilus
Normalized name: L. acidophilus/L.bulgaricus ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. acidophilus LB
Study: 9360340
Drug: Oresol-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oresol-G
Study: 3899198
Drug: Dextroamphetamine (Dex)
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (Dex) 15 mg
Study: 3899198
Drug: Fenfluramine (Fen)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (Fen) 40 mg
Study: 29887334
Drug: Bevacizumab 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 0.25 mg
Study: 29887334
Drug: Bevacizumab 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 0.125 mg
Study: 29887334
Drug: Bevacizumab 0.063
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 0.063 mg
Study: 29887334
Drug: Bevacizumab 0.031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 0.031 mg
Study: 29887334
Drug: Bevacizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (all doses)
Study: 25704503
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MFGM tablets (6.5 g) for 4 weeks
Study: 23335901
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/day, N=32)
Study: 18655523
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at 0.067 mg/kg/day
Study: 18655523
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at 0.033 mg/kg/day
Study: 16968587
Drug: Cefdinir (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (14 mg/kg divided BID)
Study: 16968587
Drug: High-dose amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin/clavulanate (90/6.4 mg/kg divided BID)
Study: 16968587
Drug: High-dose amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin/clavulanate
Study: 15523393
Drug: Radiochemotherapy (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiochemotherapy (200 mg/m²/day of intravenous 5-fluorouracil and 5040 cGy of radiotherapy)
Study: 11515713
Drug: Willow bark
Normalized name: Willow bark
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willow bark extract (Assalix) 240 mg salicin per day (group W240)
Study: 11515713
Drug: Willow bark
Normalized name: Willow bark
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willow bark extract (Assalix) 120 mg salicin per day (group W120)
Study: 11515713
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments only (group C)
Study: 9791144
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg) plus Icatibant (100 microg/kg)
Study: 9791144
Drug: Losartan (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (75 mg)
Study: 7842496
Drug: Single case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single case studies with randomized treatment
Study: 27099247
Drug: Corticotropin-releasing factor
Normalized name: corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing factor (CRF) injection
Study: 24560674
Drug: Monovalent replication-deficient
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent replication-deficient delNS1-H1N1 influenza virus vaccine (7.7log10TCID50/volunteer)
Study: 24560674
Drug: Monovalent replication-deficient
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent replication-deficient delNS1-H1N1 influenza virus vaccine
Study: 20444742
Drug: Aciclovir 800
Normalized name: Aciclovir 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 800 mg twice daily for 5 days
Study: 10950228
Drug: Tri-iodothyronine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-iodothyronine treatment (2 microg/kg bodyweight on day 1, 1 microg/kg bodyweight on subsequent days up to 12 days)
Study: 10950228
Drug: Tri-iodothyronine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-iodothyronine treatment
Study: 1282179
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg b.i.d. increased to 20 mg b.i.d. after 4 weeks)
Study: 1282179
Drug: Nicorandil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (20 mg b.i.d.)
Study: 1282179
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Nicorandil and Nifedipine)
Study: 6429850
Drug: AIO solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIO solution (40 g crystalline L-aminoacids, 38 g fat, 75 g sorbitol, 45 g xylitol in 1000 ml)
Study: 6429850
Drug: AIO solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIO solution
Study: 20536366
Drug: Conventional amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional amphotericin B at 0.7 mg/kg/day
Study: 20536366
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B at 3 mg/kg/day
Study: 20536366
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B at 6 mg/kg/day
Study: 14964349
Drug: nonretarded test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonretarded test medication
Study: 14964349
Drug: retarded reference
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: retarded reference formulation
Study: 10642807
Drug: Mobilizing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilizing therapy and first transplant
Study: 10642807
Drug: Transplant-related chemotherapy
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant-related chemotherapy
Study: 2062997
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days supply of medication
Study: 2062997
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days supply of medication
Study: 2062997
Drug: New discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: New discharge letter with prescription details
Study: 25407966
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (radiotherapy + LMP1-targeted DNAzyme)
Study: 23135655
Drug: Cetaphil Dermacontrol
Normalized name: CETAPHIL
DrugBank: Octocrylene (DB09535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetaphil Dermacontrol Moisturizer (CDM) + tretinoin cream 0.05%
Study: 23135655
Drug: tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tretinoin cream 0.05%
Study: 15883262
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg; two 40‐mg tablets once daily)
Study: 9607039
Drug: Oral inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 001)
Study: 9607039
Drug: Oral inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 003)
Study: 9607039
Drug: Oral inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inactivated enterotoxigenic Escherichia coli vaccine
Study: 2667153
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg twice a day for seven days)
Study: 2667153
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg twice a day for seven days)
Study: 790287
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (10 mg/kg three times per day)
Study: 21715702
Drug: Pramipexole (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.25 mg)
Study: 21993434
Drug: Hoodia gordonii
Normalized name: Hoodia gordonii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hoodia gordonii purified extract (HgPE) 1110 mg, 2 servings/day for 15 days
Study: 1382540
Drug: Cryotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy and inosine pranobex 60 mg/kg/day for 1 week each month
Study: 26752328
Drug: Individual in
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual in vivo exposure therapy (iVET)
Study: 26752328
Drug: Individual virtual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual virtual reality exposure therapy (VRET)
Study: 22343689
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml fibrin sealant
Study: 22343689
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml fibrin sealant